U.S. Influenza Vaccines Market, by Vaccine Type (Trivalent Vaccines and Quadrivalent Vaccines), by Virus Type (Influenza Virus Type A and Influenza Virus Type B) and by Age Group (Pediatrics and Adults) - Trends, and Forecast till 2025

U.S. Influenza Vaccines Market– Prevention of Virus through Vaccination Aids in Reducing Burden of the Disease

Influenza is an infection caused by influenza virus and is commonly known as flu. Vaccination for influenza aids in prevention of flu. This vaccine is recommended for children aged 6 months and older. According to the World health Organization (WHO), 2017, Influenza virus is transmitted primarily by respiratory secretions or droplets of the infected person. It has an annual global attack rate of 5–10% in adults and 20–30% in children. Influenza vaccines are available with a wide range of options for different age groups i.e. children aged 6 months and above and adults aged 65 and above. According to the American Public Health Association, 2015, Influenza vaccines confer protection with 60–90% efficacy among the recipients, thus increasing the adoption rate of the vaccines.

The U.S. influenza vaccines market was valued at US$ 2.1 billion in 2016 and is expected to witness a CAGR of 15.9% over the forecast period (2017–2025).

Request Sample Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1127

Rising incidence of pandemic events and increasing awareness, leading to improved pandemic preparedness is expected to boost the market growth

Rising pandemic events is mainly attributed to genetic diversity of influenza viruses with varying patterns and severity. Risk of the onset of a novel pandemic strain has resulted in rise in research and development for production of efficacious influenza vaccines. Pandemic planning is expected to reduce transmission of pandemic virus, which can eventually decrease hospitalizations and deaths, thus minimizing the social and economic impact of pandemic events. According to the World Health Organization, in 2015, around 233 million outpatient visits, 5.2 million hospital admissions, and 7.4 million deaths are expected to manifest if a pandemic event were to occur, globally. Also, the Centers for Medicare & Medicaid Services (CMS) provides reimbursement covering 100% of the costs of one seasonal influenza virus vaccinations per influenza season, and it also covers additional seasonal influenza virus vaccinations. Thus, favorable reimbursement is a positive factor to increase adoption rates of influenza vaccines, thus propelling the market growth. However, shortage of vaccine supply due to genetic assortment of the viral strains is surging the need for updating vaccines each year by the manufacturers. This is a major factor restraining market growth.

The key players operating in the influenza vaccines market include Sanofi Pasteur, Seqirus Vaccines Ltd., GlaxoSmithKline Plc., and Medimmune.

Browse The Complete Report @ https://www.coherentmarketinsights.com/press-release/us-influenza-vaccines-market-to-surpass-us-80-billion-threshold-by-2025-519

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentnews.com

This release was published on openPR.